Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.1663
Abstract: Atrial fibrillation (AF) is common in patients with diabetes and heart failure (HF) and increases the future risk of adverse cardiovascular (CV) outcomes. This analysis from the EMPA‐REG OUTCOME trial explores CV and renal outcomes… read more here.
Keywords: atrial fibrillation; heart; heart failure; empa reg ... See more keywords
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA‐REG OUTCOME trial
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.2220
Abstract: Loop diuretics (LD) relieve symptoms and signs of congestion due to heart failure (HF), but many patients prescribed LD do not have such a diagnosis. We studied the relationship between HF diagnosis, use of LD,… read more here.
Keywords: patients type; outcomes patients; outcome trial; type diabetes ... See more keywords
Cancer risk in the EMPA-REG OUTCOME trial. Reply to Shaikh AMY [letter] and Kohler S, Lee J, George JT et al [letter]
Sign Up to like & getrecommendations! Published in 2017 at "Diabetologia"
DOI: 10.1007/s00125-017-4431-z
Abstract: To the Editor: We strongly but respectfully disagree with the letter by Dr. Shaikh [1] regarding an issue with the reporting of the number of cases of bladder cancer from the EMPA-REG OUTCOME Trial [2]… read more here.
Keywords: bladder cancer; trial; letter; empa reg ... See more keywords
Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
Sign Up to like & getrecommendations! Published in 2017 at "Diabetes Therapy"
DOI: 10.1007/s13300-017-0229-8
Abstract: BackgroundSodium-glucose co-transporter-2 (SGLT2) inhibitors (gliflozins) are the newest class of medication available to treat type 2 diabetes (T2DM). Recent findings from the first complete cardiovascular safety trial in SGLT2 inhibitors, the Empagliflozin, Cardiovascular Outcomes, and… read more here.
Keywords: sglt2 inhibitors; real world; trial; empa reg ... See more keywords
THE ASSOCIATION BETWEEN URIC ACID LEVELS AND CARDIORENAL OUTCOMES AND DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(19)32360-5
Abstract: Plasma uric acid (UA) has been proposed as a biomarker of cardiovascular (CV) risk, but data are limited. UA levels may also modulate the effectiveness of CV risk reduction therapies. In EMPA-REG OUTCOME, patients (N=7020)… read more here.
Keywords: association uric; reg outcome; uric acid; type diabetes ... See more keywords
P2629Early benefits of empagliflozin in patients with type 2 diabetes with heart failure are not offset by increased adverse events: results from the EMPA-REG OUTCOME trial
Sign Up to like & getrecommendations! Published in 2019 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehz748.0952
Abstract: The cardiovascular (CV) benefits of sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) have been demonstrated in long-term clinical trials. In the EMPA-REG OUTCOME trial, the SGLT2 inhibitor empagliflozin (EMPA), compared with… read more here.
Keywords: heart; year; outcome trial; empa reg ... See more keywords
Highlights from the 77th Scientific Sessions of the American Diabetes Association Scientific Meeting, 9‐13 June 2017, San Diego, USA
Sign Up to like & getrecommendations! Published in 2017 at "Diabetes"
DOI: 10.1111/dom.13058
Abstract: The much waited presentation at this year’s ADA meeting was the integrated analysis of the CANVAS and CANVAS-R trials which formed the landmark CANVAS Program. The trial, funded by Jansen Pharmaceuticals, showed that canagliflozin (Invokana)… read more here.
Keywords: amputation; risk; meeting; disease ... See more keywords
Sodium‐glucose co‐transporter‐2 inhibitors and protection from cardiovascular death: Is it all about heart failure?
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.1111/dom.14444
Abstract: To the Editor: The results of the EMPA-REG Outcome trial heralded the cardiovascular (CV) relevance of sodium-glucose co-transporter-2 inhibitors (SGLT-2is), showing an unprecedented reduction of CV death by 38% over standard of care. Then, results… read more here.
Keywords: death; analysis; sglt 2is; empa reg ... See more keywords
Class effects of SGLT2 inhibitors on cardiorenal outcomes
Sign Up to like & getrecommendations! Published in 2019 at "Cardiovascular Diabetology"
DOI: 10.1186/s12933-019-0903-4
Abstract: BackgroundTo summarize the four recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing… read more here.
Keywords: class effects; credence; canvas; empa reg ... See more keywords
Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
Sign Up to like & getrecommendations! Published in 2020 at "Cardiovascular Diabetology"
DOI: 10.1186/s12933-020-01174-6
Abstract: Background Patients with type 2 diabetes (T2D) and metabolic syndrome (MetS) are at greater cardiovascular risk than those with T2D without MetS. In the current report we aim to study the characteristics, cardio-renal outcomes and… read more here.
Keywords: patients type; trial; cardio renal; type diabetes ... See more keywords
Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes Care"
DOI: 10.2337/dci21-0009
Abstract: We acknowledge the thought-provoking hypothesis that Brikman and Dori (1) suggest to explain the lower incidence of new-onset obstructive sleep apnea (OSA) observed among participants treated with empagliflozin compared with placebo we recently reported. They… read more here.
Keywords: co2; sleep; empa reg; obstructive sleep ... See more keywords